Two patients with MLL-rearranged B-ALL treated with CD19 CAR T cells on the SCRI trial [33] and one patient from the Fred Hutchinson Cancer Center [10] were reported to experience a lineage switch with CD19-negative escape after CD19 CAR T cell therapy. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.